These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36111555)

  • 21. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States.
    Adams K; Rhoads JP; Surie D; Gaglani M; Ginde AA; McNeal T; Ghamande S; Huynh D; Talbot HK; Casey JD; Mohr NM; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hicks M; Hager DN; Ali H; Prekker ME; Frosch AE; Exline MC; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Lauring AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Chappell JD; Halasa N; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Lindsell CJ; Hart KW; Lester SN; Thornburg NJ; Park S; McMorrow ML; Patel MM; Tenforde MW; Self WH
    medRxiv; 2022 Jun; ():. PubMed ID: 35734090
    [No Abstract]   [Full Text] [Related]  

  • 22. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
    Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
    BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA vaccine effectiveness against hospitalisation due to severe acute respiratory infection (SARI) COVID-19 during Omicron variant predominance estimated from real-world surveillance data, Slovenia, February to March 2022.
    Grgič Vitek M; Klavs I; Učakar V; Vrh M; Mrzel M; Serdt M; Fafangel M
    Euro Surveill; 2022 May; 27(20):. PubMed ID: 35593166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Seppälä E; Dahl J; Veneti L; Rydland KM; Klüwer B; Rohringer A; Meijerink H
    Vaccine; 2024 Jan; 42(3):620-628. PubMed ID: 38142215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study.
    Stowe J; Andrews N; Kirsebom F; Ramsay M; Bernal JL
    Nat Commun; 2022 Sep; 13(1):5736. PubMed ID: 36180428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study.
    Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L
    Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
    Monge S; Humphreys J; Nicolay N; Braeye T; Van Evercooren I; Holm Hansen C; Emborg HD; Sacco C; Mateo-Urdiales A; Castilla J; Martínez-Baz I; de Gier B; Hahné S; Meijerink H; Kristoffersen AB; Machado A; Soares P; Nardone A; Bacci S; Kissling E; Nunes B;
    Influenza Other Respir Viruses; 2024 Apr; 18(4):e13292. PubMed ID: 38654485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
    McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
    Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
    Klein NP; Stockwell MS; Demarco M; Gaglani M; Kharbanda AB; Irving SA; Rao S; Grannis SJ; Dascomb K; Murthy K; Rowley EA; Dalton AF; DeSilva MB; Dixon BE; Natarajan K; Stenehjem E; Naleway AL; Lewis N; Ong TC; Patel P; Konatham D; Embi PJ; Reese SE; Han J; Grisel N; Goddard K; Barron MA; Dickerson M; Liao IC; Fadel WF; Yang DH; Arndorfer J; Fireman B; Griggs EP; Valvi NR; Hallowell C; Zerbo O; Reynolds S; Ferdinands J; Wondimu MH; Williams J; Bozio CH; Link-Gelles R; Azziz-Baumgartner E; Schrag SJ; Thompson MG; Verani JR
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):352-358. PubMed ID: 35239634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Effectiveness of COVID-19 Vaccination in Healthcare Workers: 3-Dose Versus 2-Dose Vaccination.
    Kim SR; Kang HJ; Jeong HR; Jang SY; Lee JE; Kim DE; Lee HR; Cho MH; Noh JY; Cheong HJ; Kim WJ; Song JY
    J Korean Med Sci; 2022 Sep; 37(35):e267. PubMed ID: 36065651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill-An interim analysis of a nationwide cohort study.
    Baum U; Poukka E; Palmu AA; Salo H; Lehtonen TO; Leino T
    PLoS One; 2021; 16(11):e0258704. PubMed ID: 34793476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
    Grewal R; Kitchen SA; Nguyen L; Buchan SA; Wilson SE; Costa AP; Kwong JC
    BMJ; 2022 Jul; 378():e071502. PubMed ID: 35793826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.
    Cerqueira-Silva T; de Araujo Oliveira V; Paixão ES; Júnior JB; Penna GO; Werneck GL; Pearce N; Barreto ML; Boaventura VS; Barral-Netto M
    Nat Commun; 2022 Jul; 13(1):4154. PubMed ID: 35851597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.
    Andrews N; Stowe J; Kirsebom F; Toffa S; Sachdeva R; Gower C; Ramsay M; Lopez Bernal J
    Nat Med; 2022 Apr; 28(4):831-837. PubMed ID: 35045566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
    Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years.
    Arbel R; Sergienko R; Friger M; Peretz A; Beckenstein T; Yaron S; Netzer D; Hammerman A
    Nat Med; 2022 Jul; 28(7):1486-1490. PubMed ID: 35468276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
    Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
    BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.